TREDOL 100MG TABLETS

国: キプロス

言語: ギリシャ語

ソース: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

有効成分:

ATENOLOL

から入手可能:

DELORBIS PHARMACEUTICALS LTD (0000009620) 17 ATHINON STREET, ERGATES INDUSTRIAL AREA, LEFKOSIA, 2081, 28629

ATCコード:

C07AB03

INN（国際名）:

ATENOLOL

投薬量:

100MG

医薬品形態:

TABLETS

構図:

ATENOLOL (0029122687) 100MG

投与経路:

ORAL USE

処方タイプ:

Εθνική Διαδικασία

治療領域:

ATENOLOL

製品概要:

Νομικό καθεστώς: Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 20 TABS IN BLISTER(S) (240001401) 20 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται

情報リーフレット

COMPARATIVE TABLE OF PIL-EN VS PIL-GR
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TREDOL 25 MG TABLETS
TREDOL 50 MG TABLETS
TREDOL 100 MG TABLETS
Atenolol
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE
BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their signs of illness are the same
as
yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes
any possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What Tredol is and what it is used for
2. What you need to know before you take Tredol
3. How to take Tredol
4. Possible side effects
5. How to store Tredol
6. Contents of the pack and other information
1. WHAT TREDOL IS AND WHAT IT IS USED FOR
ΦΎΛΛΟ ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ: ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ
ΤΟΝ ΑΣΘΕΝΉ
TREDOL 25 MG ΔΙΣΚΊΑ
TREDOL 50 MG ΔΙΣΚΊΑ
TREDOL 100 MG ΔΙΣΚΊΑ
Ατενολόλη
ΔΙΑΒΆΣΤΕ ΠΡΟΣΕΚΤΙΚΆ ΟΛΌΚΛΗΡΟ ΤΟ ΦΎΛΛΟ
ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ ΠΡΙΝ ΑΡΧΊΣΕΤΕ
ΝΑ
ΠΑΊΡΝΕΤΕ
ΑΥΤΌ
ΤΟ
ΦΆΡΜΑΚΟ,
ΔΙΌΤΙ
ΠΕΡΙΛΑΜΒΆΝΕΙ
ΣΗΜΑΝΤΙΚΈΣ
ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ ΣΑΣ.

Φυλάξτε αυτό το φύλλο οδηγιών χρήσης.
Ίσως χρειαστεί να το διαβάσετε
ξανά.

Εάν έχετε περαιτέρω απορίες, ρωτήστε
το γιατρό ή το φαρμακοποιό σας.

Η συνταγή για αυτό το φάρμακο
χορηγήθηκε αποκλειστικά για σας. Δεν
πρέπει να δώσετε το φάρμακο σε άλλους.
Μπορεί να τους προκαλέσει
βλάβη, ακόμα και όταν τα σημεία της
ασθένειάς τους ε�

製品の特徴

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICAL PRODUCT
Tredol 25 mg Tablets
Tredol 50 mg Tablets
Tredol 100 mg Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
For 25 mg strength:
Each tablet contains 25 mg atenolol.
For 50 mg strength:
Each tablet contains 50 mg atenolol.
For 100 mg strength:
Each tablet contains 100 mg atenolol.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets.
Tredol 25 mg:
White, flat, round tablets, 8mm diameter in size, cross-scored on one
side.
Tredol 50 mg:
White, concave, round tablets, 9mm diameter in size, scored on one
side.
Tredol 100 mg:
White, flat, round tablets, 12mm diameter in size, scored on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Tredol is indicated in the treatment of:
•
Management of hypertension.
•
Management of angina pectoris.
•
Management of cardiac arrhythmias.
•
Management of myocardial infarction. Early intervention in the acute
phase.
1
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
The dose must always be adjusted to individual requirements of the
patients, with the lowest
possible starting dosage. The following are guidelines:
ADULTS
HYPERTENSION
One tablet daily. Most patients respond to 100 mg daily given orally
as a single dose. Some
patients, however, will respond to 50 mg given as a single daily dose.
The effect will be fully
established after one to two weeks. Α further reduction in blood
pressure may be achieved by
combining atenolol with other antihypertensive agents. For example,
co-administration of
atenolol with a diuretic, as in Atenolol/Chlortalidone, provides a
highly effective and
convenient antihypertensive therapy.
ANGINA
Most patients with angina pectoris will respond to 100 mg given orally
once daily or 50 mg
given twice daily. It is unlikely that additional benefit will be
gained by increasing the dose.
CARDIAC ARRHYTHMIAS
A suitable initial dose of atenolol is 2.5 mg (5 ml) injected
intravenously over a 2.5 minute
period (i.e. 1 mg/minute). (See also prescribing i